Trial Profile
Exploratory study of prediction marker for efficacy and safety of TBI-1301
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Aug 2022
Price :
$35
*
At a glance
- Drugs Mipetresgene autoleucel (Primary)
- Indications Solid tumours
- Focus Pharmacodynamics; Therapeutic Use
- 12 Aug 2022 Status changed from active, no longer recruiting to completed.
- 09 Feb 2020 Status changed from recruiting to active, no longer recruiting.
- 28 Dec 2018 Status changed from not yet recruiting to recruiting.